Unmet Needs in NMIBC

Author(s):

Chad A. Reichard, MD ,Karim Chamie, MD, MSHS

Experts discuss the unmet needs in the treatment of non–muscle-invasive bladder cancer (NMIBC), highlighting areas where advancements are still needed.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Standard of Care and Intravesical Chemotherapy in NMIBC

EP: 2.BCG for treatment of NMIBC

EP: 3.Cystectomy in NMIBC

EP: 4.New Intravesical Delivery Systems and TAR-200 in NMIBC

EP: 5.TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP: 6.TAR-200 Clinical Development Program in NMIBC

EP: 7.Other Investigational Drug Delivery Systems in NMIBC

EP: 8.Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

EP: 9.FDA-Approved Treatments for BCG-Unresponsive NMIBC

EP: 10.Use and Sequencing of Novel Treatments in NMIBC

EP: 11.Communication of Treatment Options for High-Risk NMIBC

EP: 12.Checkpoint Inhibitors for Treatment of NMIBC

Now Viewing

EP: 13.Unmet Needs in NMIBC

EP: 14.Operationalizing TAR-200 and Other Delivery Systems in Practice

EP: 15.Patient Communication and Treatment Adherence in NMIBC

EP: 16.Uptake of New Treatments in Urology Practice

EP: 17.Final Thoughts and Clinical Trials in NMIBC

Video content above is prompted by the following:

What are some unmet needs in NMIBC?

Related Videos

Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

Treatment or Lack of Treatment of Small Renal Masses

The current treatment landscape of mHSPC

Strengths and Weaknesses of Imaging Modalities in ccRCC

BPH: Strategies for Guiding Patients From Medication to Intervention

Representation of Black men with mHSPC in clinical trials

Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses

Non–Muscle Invasive-Bladder Cancer Overview

NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up

BRCA Mutations in mHSPC: Impact on Therapy Selection